Children < 18 years <br/ >Pregnant or lactating women <br/ >Symptoms of acute respiratory tract infection for > 10d before randomisation <br/ >More than 48h have elapsed between meeting inclusion criteria and randomisation <br/ >Seizure disorder <br/ >Known case of G6PD deficiency <br/ >Diagnosed long QT syndrome <br/ >QTc >500ms on ECG within 72h prior to enrolment <br/ >Chronic haemodialysis or GFR <20 ml/min <br/ >Psoriasis or porphyria cutanea tarda <br/ >Severe liver disease <br/ >Any subject who has received the following drugs in the 12h period before enrolment or who is likely to receive the following during the period of therapy with HCQ / HCQ + AZT / AZT: amiodarone, cimetidine, phenobarbitone, phenytoin, digoxin <br/ >Receipt of >1 dose of HCQ / AZT in 10 days prior to enrolment <br/ >Known allergic reactions to HCQ or azithromycin <br/ >Inability to take/receive enteral medication <br/ >Inability to be contacted on D14 for clinical outcome assessment (unless died in hospital)

Children < 18 years <br/ >Pregnant or lactating women <br/ >Symptoms of acute respiratory tract infection for > 10d before randomisation <br/ >More than 48h have elapsed between meeting inclusion criteria and randomisation <br/ >Seizure disorder <br/ >Known case of G6PD deficiency <br/ >Diagnosed long QT syndrome <br/ >QTc >500ms on ECG within 72h prior to enrolment <br/ >Chronic haemodialysis or GFR <20 ml/min <br/ >Psoriasis or porphyria cutanea tarda <br/ >Severe liver disease <br/ >Any subject who has received the following drugs in the 12h period before enrolment or who is likely to receive the following during the period of therapy with HCQ / HCQ + AZT / AZT: amiodarone, cimetidine, phenobarbitone, phenytoin, digoxin <br/ >Receipt of >1 dose of HCQ / AZT in 10 days prior to enrolment <br/ >Known allergic reactions to HCQ or azithromycin <br/ >Inability to take/receive enteral medication <br/ >Inability to be contacted on D14 for clinical outcome assessment (unless died in hospital)

N/A

N/A

Children < 18 years <br/ >Pregnant or lactating women <br/ >Symptoms of acute respiratory tract infection for > 10d before randomisation <br/ >More than 48h have elapsed between meeting inclusion criteria and randomisation <br/ >Seizure disorder <br/ >Known case of G6PD deficiency <br/ >Diagnosed long QT syndrome <br/ >QTc >500ms on ECG within 72h prior to enrolment <br/ >Chronic haemodialysis or GFR <20 ml/min <br/ >Psoriasis or porphyria cutanea tarda <br/ >Severe liver disease <br/ >Any subject who has received the following drugs in the 12h period before enrolment or who is likely to receive the following during the period of therapy with HCQ / HCQ + AZT / AZT: amiodarone, cimetidine, phenobarbitone, phenytoin, digoxin <br/ >Receipt of >1 dose of HCQ / AZT in 10 days prior to enrolment <br/ >Known allergic reactions to HCQ or azithromycin <br/ >Inability to take/receive enteral medication <br/ >Inability to be contacted on D14 for clinical outcome assessment (unless died in hospital)

Children < 18 years <br/ >Pregnant or lactating women <br/ >Symptoms of acute respiratory tract infection for > 10d before randomisation <br/ >More than 48h have elapsed between meeting inclusion criteria and randomisation <br/ >Seizure disorder <br/ >Known case of G6PD deficiency <br/ >Diagnosed long QT syndrome <br/ >QTc >500ms on ECG within 72h prior to enrolment <br/ >Chronic haemodialysis or GFR <20 ml/min <br/ >Psoriasis or porphyria cutanea tarda <br/ >Severe liver disease <br/ >Any subject who has received the following drugs in the 12h period before enrolment or who is likely to receive the following during the period of therapy with HCQ / HCQ + AZT / AZT: amiodarone, cimetidine, phenobarbitone, phenytoin, digoxin <br/ >Receipt of >1 dose of HCQ / AZT in 10 days prior to enrolment <br/ >Known allergic reactions to HCQ or azithromycin <br/ >Inability to take/receive enteral medication <br/ >Inability to be contacted on D14 for clinical outcome assessment (unless died in hospital)